Phaseline

Companies › Therorna

Therorna: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Immunology, Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TI-0032-III injection
Lipid nanoparticle-formulated circular RNA encoding CD19 chimeric antigen receptor (CAR)
CD19Phase 1Systemic Lupus Erythematosus (SLE)May 2027
TI-0093 injection
therapeutic tumor vaccine targeting HPV-16
–Phase 1HPV 16+ Recurrent or Metastatic CancerJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07413341TI-0032-III injectionPhase 1Systemic Lupus Erythematosus (SLE)ImmunologyMay 2027
NCT07081984TI-0093 injectionPhase 1HPV 16+ Recurrent or Metastatic CancerOncologyJul 2027

Targets

CD19 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology iCell Gene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.